Here is where aggressive traders could go long the cancer therapy name.
The charts suggest further weakness is possible.
At current levels BMY is sort-of in no man's land - not bullish and not bearish.
Karyopharm Therapeutics and Gamida Cell are promising companies that have seen their shares pull back significantly in recent weeks.
HALO now looks like it can correct to the $34 to $30 area in the weeks ahead.
A break in a key support level could precipitate further declines in the life sciences company's shares.
Let's take a look at the charts and indicators.
Let's stand aside for now and see how things unfold.
Our latest analysis and trading strategy on NVCR.
It might be best to wait for a pullback in shares of the diagnostic and testing company before buying.